|
05 May 2022 |
Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers
|
|
05 May 2022 |
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
|
|
05 May 2022 |
Farxiga met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
|
|
04 May 2022 |
STORM Therapeutics Awarded Innovate UK Grant to Discover and Develop a Novel Coronavirus Therapy Targeting an RNA-Modifying Enzyme
|
|
04 May 2022 |
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
|
|
04 May 2022 |
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
|
|
01 May 2022 |
U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms
|
|
01 May 2022 |
RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis
|
|
28 Apr 2022 |
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
|
|
28 Apr 2022 |
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
|
|
26 Apr 2022 |
Priothera Receives FDA clearance of Investigational New Drug (IND) to start Phase 2b/3 study with mocravimod in Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
|
|
24 Apr 2022 |
New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance
|
|
20 Apr 2022 |
SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma
|
|
20 Apr 2022 |
SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
|
|
20 Apr 2022 |
BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications
|
|
15 Apr 2022 |
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
|
|
13 Apr 2022 |
Adiso Therapeutics Announces Completion of First Cohort Enrollment in a Phase 1b Study of ADS051 for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
|
|
13 Apr 2022 |
Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders
|
|
13 Apr 2022 |
Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting
|
|
13 Apr 2022 |
OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR 2022 Annual Meeting
|
|
12 Apr 2022 |
Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma
|
|
12 Apr 2022 |
Linnaeus Therapeutics Announces Presentation of Pre-Clinical Data of LNS8801 at 2022 AACR Annual Meeting
|
|
12 Apr 2022 |
Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting
|
|
11 Apr 2022 |
InventisBio Reported Promising Phase I Study Results of a Novel KRAS G12C Inhibitor D-1553 in Cancer Patients
|
|
11 Apr 2022 |
Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276 in patients with Advanced Solid Tumors and Hodgkin's Lymphoma
|
